Adalimumab, a novel TNF-α inhibitor, has been proven to be effective in long-term remission of ocular inflammation, sparing systemic GCs, and rescue of visual acuity, mostly by experience and studies on uveitis [29,30,31]. The gene discussed is TNF; the disease is uveitis.